News
1d
Zacks Investment Research on MSNModerna to Report Q2 Earnings: Is a Beat in Store for the Stock?We expect Moderna MRNA to surpass expectations when it reports second-quarter 2025 earnings on Aug. 1, before the opening ...
1d
Zacks Investment Research on MSNCurious about Moderna (MRNA) Q2 Performance? Explore Wall Street Estimates for Key MetricsThe upcoming report from Moderna (MRNA) is expected to reveal quarterly loss of -$2.99 per share, indicating an increase of 10.2% compared to the year-ago period. Analysts forecast revenues of $127.17 ...
This stock used to be a highflyer but has struggled in recent years as demand waned for its flagship product. Though Moderna ...
The main reason for the downturn in Moderna’s stock is a significant drop in the demand for its COVID-19 vaccine. After experiencing remarkable growth during the pandemic with its groundbreaking ...
An explosive phase of growth may be ahead thanks to several potential product launches. A lot can happen in 10 years, and that's good news for a struggling stock like Moderna (NASDAQ: MRNA).
It also intends to present data from the P304 study at a future medical meeting. MRNA Stock Price Performance Post the above news, shares of Moderna rose nearly 2% yesterday.
That surely came as a relief to Moderna investors, since the company's latest stock-rattling news was its withdrawal of a Food and Drug Administration application for a combination COVID-19/flu ...
Moderna faces revenue declines, regulatory setbacks, and market challenges as COVID-19 vaccine demand wanes. Learn more about MRNA stock here.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results